Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2014/08/22 13:22
2014/08/22 13:22
18h
Biotech Stock Mailbag: Threshold, Galena, CytRx BOSTON (TheStreet) -- A late summer Biotech Stock Mailbag. Sean L. writes: Big fan and follower of all things biotech. I came across the...
2014/08/22 13:22
2014/08/22 13:22
Latest videos
2014/08/21 11:22
2014/08/21 11:22
1d
Updated from 6:07 am EDT with additional Galena comment.Lake Oswego, Oreg. (TheStreet) -- Galena Biopharma(GALE) CEO Mark Ahn was fired by the board of directors at a special meeting held Monday,...
2014/08/20 10:22
2014/08/20 10:22
2d
CRANBURY, NJ (TheStreet) -- Amicus Therapeutics(FOLD) CEO John Crowley came close to permanently shelving his company's experimental Fabry disease therapy following disappointing results from a...
2014/08/15 12:22
2014/08/15 12:22
7d
BOSTON (TheStreet) -- Welcome back to the Biotech Stock Mailbag. Richard V. asks: Adam, I follow you on Twitter and saw you comment on Exact Sciences(EXAS) and the pricing of Cologuard. Can you...
2014/08/11 12:22
2014/08/11 12:22
11d
... impressed me with his ambition and his knowledge of drug development, which is why I am invested in the company," said another Retrophin shareholder who asked not be identified by name. "But...
2014/08/11 11:22
2014/08/11 11:22
11d
Sanofi (SNY), an established Big Pharma player in the global diabetes market, will market Afrezza worldwide in exchange for a $150 million upfront license fee paid to MannKind. The two companies will...
2014/08/07 00:17
2014/08/07 00:17
16d
If you purchased or acquired Galectin publicly traded securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than September 29, 2014. A lead plaintiff...
2014/08/01 12:22
2014/08/01 12:22
21d
BOSTON (TheStreet) -- A discussion of an experimental hepatitis B therapy kicks off this week's Biotech Stock Mailbag. Arrowhead is conducting a phase IIa study of ARC-520 in hepatitis B patients,...
2014/07/31 21:22
2014/07/31 21:22
22d
NEW YORK (TheStreet) -- U.S. stock markets plummeted on volatile trading Thursday as mixed earnings reports, concerns about the health of the European economy and financial sector and the wait for...
2014/07/31 13:22
2014/07/31 13:22
22d
You're not hallucinating. This longtime Amarin bear believes there's now a compelling argument for going long the stock or its options -- if only for a speculative trade. The idea of being long Amarin...
2014/07/30 16:22
2014/07/30 16:22
23d
Aegerion reported Juxtapid sales of $36 million in the second quarter, a hair higher than the Street's $35 million consensus estimate. More importantly, Aegerion refined its 2014 Juxtapid sales...
2014/07/29 19:17
2014/07/29 19:17
24d
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Galectin Therapeutics Inc.(NASDAQ: GALT)...
2014/07/25 12:22
2014/07/25 12:22
28d
Intercept Pharma Shares Soaring on Positive Liver Disease Study Results (Updated) Shares of Intercept Pharmaceuticals(ICPT) have almost tripled early Thursday morning on the announcement of positive...
2014/07/18 13:58
2014/07/18 13:58
m
For perspective, here's a chart of the IBB and XBI performance year to date. It's too early to say anything conclusive, of course, but it does look like Yellen may have cut short the biotech recovery...
2014/07/17 15:22
2014/07/17 15:22
m
NEW YORK (TheStreet) -- Bluebird Bio(BLUE) excited investors last month with the release of data from a clinical trial showing the first two beta-thalassemia patients treated with the gene therapy...
2014/08/22 13:22
2014/08/22 13:22
Latest from Twitter